Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine

Anja Krause, Yaqin Xu, Sara Ross, Wendy Wu, Ju Joh, Stefan Worgall

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The development of a vaccine against respiratory syncytial virus (RSV) has been hampered by the risk for vaccine-enhanced RSV pulmonary disease induced by immunization with formalin-inactivated RSV (FIRSV). This study focuses on the evaluation of vaccine-enhanced pulmonary disease following immunization with AdF.RGD, an integrin-targeted adenovirus vector that expresses the RSV F protein and includes an RGD (Arg-Gly-Asp) motif. Immunization of BALB/c mice with AdF.RGD, resulted in anti-RSV protective immunity and induced increased RSV-specific IFN- T cell responses compared to FIRSV. RSV infection 5 wk after immunization with FIRSV induced pulmonary inflammatory responses in the lung, that was not observed with AdF.RGD. Additionally, In the FIRSV-immunized mice following infection with RSV, pulmonary DC increased and Tregs decreased. This suggests that distinct responses of pulmonary DC and Tregs are a features of vaccine-enhanced RSV disease and that immunization with an RGD-modified Ad vaccine does not trigger vaccine-enhanced disease.

Original languageEnglish (US)
Article number375
JournalVirology Journal
Volume8
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Respiratory Syncytial Virus Vaccines
Virus Diseases
Adenoviridae
Respiratory Syncytial Viruses
Dendritic Cells
Immunization
Vaccines
Formaldehyde
Lung
Respiratory Syncytial Virus Infections
Lung Diseases
Integrins
Immunity
T-Lymphocytes
Proteins

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. / Krause, Anja; Xu, Yaqin; Ross, Sara; Wu, Wendy; Joh, Ju; Worgall, Stefan.

In: Virology Journal, Vol. 8, 375, 2011.

Research output: Contribution to journalArticle

Krause, Anja ; Xu, Yaqin ; Ross, Sara ; Wu, Wendy ; Joh, Ju ; Worgall, Stefan. / Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. In: Virology Journal. 2011 ; Vol. 8.
@article{d32bba56ad5242f189fa725b7e1bbcd3,
title = "Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine",
abstract = "The development of a vaccine against respiratory syncytial virus (RSV) has been hampered by the risk for vaccine-enhanced RSV pulmonary disease induced by immunization with formalin-inactivated RSV (FIRSV). This study focuses on the evaluation of vaccine-enhanced pulmonary disease following immunization with AdF.RGD, an integrin-targeted adenovirus vector that expresses the RSV F protein and includes an RGD (Arg-Gly-Asp) motif. Immunization of BALB/c mice with AdF.RGD, resulted in anti-RSV protective immunity and induced increased RSV-specific IFN- T cell responses compared to FIRSV. RSV infection 5 wk after immunization with FIRSV induced pulmonary inflammatory responses in the lung, that was not observed with AdF.RGD. Additionally, In the FIRSV-immunized mice following infection with RSV, pulmonary DC increased and Tregs decreased. This suggests that distinct responses of pulmonary DC and Tregs are a features of vaccine-enhanced RSV disease and that immunization with an RGD-modified Ad vaccine does not trigger vaccine-enhanced disease.",
author = "Anja Krause and Yaqin Xu and Sara Ross and Wendy Wu and Ju Joh and Stefan Worgall",
year = "2011",
doi = "10.1186/1743-422X-8-375",
language = "English (US)",
volume = "8",
journal = "Virology Journal",
issn = "1743-422X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine

AU - Krause, Anja

AU - Xu, Yaqin

AU - Ross, Sara

AU - Wu, Wendy

AU - Joh, Ju

AU - Worgall, Stefan

PY - 2011

Y1 - 2011

N2 - The development of a vaccine against respiratory syncytial virus (RSV) has been hampered by the risk for vaccine-enhanced RSV pulmonary disease induced by immunization with formalin-inactivated RSV (FIRSV). This study focuses on the evaluation of vaccine-enhanced pulmonary disease following immunization with AdF.RGD, an integrin-targeted adenovirus vector that expresses the RSV F protein and includes an RGD (Arg-Gly-Asp) motif. Immunization of BALB/c mice with AdF.RGD, resulted in anti-RSV protective immunity and induced increased RSV-specific IFN- T cell responses compared to FIRSV. RSV infection 5 wk after immunization with FIRSV induced pulmonary inflammatory responses in the lung, that was not observed with AdF.RGD. Additionally, In the FIRSV-immunized mice following infection with RSV, pulmonary DC increased and Tregs decreased. This suggests that distinct responses of pulmonary DC and Tregs are a features of vaccine-enhanced RSV disease and that immunization with an RGD-modified Ad vaccine does not trigger vaccine-enhanced disease.

AB - The development of a vaccine against respiratory syncytial virus (RSV) has been hampered by the risk for vaccine-enhanced RSV pulmonary disease induced by immunization with formalin-inactivated RSV (FIRSV). This study focuses on the evaluation of vaccine-enhanced pulmonary disease following immunization with AdF.RGD, an integrin-targeted adenovirus vector that expresses the RSV F protein and includes an RGD (Arg-Gly-Asp) motif. Immunization of BALB/c mice with AdF.RGD, resulted in anti-RSV protective immunity and induced increased RSV-specific IFN- T cell responses compared to FIRSV. RSV infection 5 wk after immunization with FIRSV induced pulmonary inflammatory responses in the lung, that was not observed with AdF.RGD. Additionally, In the FIRSV-immunized mice following infection with RSV, pulmonary DC increased and Tregs decreased. This suggests that distinct responses of pulmonary DC and Tregs are a features of vaccine-enhanced RSV disease and that immunization with an RGD-modified Ad vaccine does not trigger vaccine-enhanced disease.

UR - http://www.scopus.com/inward/record.url?scp=79960862349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960862349&partnerID=8YFLogxK

U2 - 10.1186/1743-422X-8-375

DO - 10.1186/1743-422X-8-375

M3 - Article

C2 - 21801372

AN - SCOPUS:79960862349

VL - 8

JO - Virology Journal

JF - Virology Journal

SN - 1743-422X

M1 - 375

ER -